2,3-Bisphosphoglycerate
Conditions
Keywords
Remote ischemic conditioning, 2,3-Bisphosphoglycerate, Erythrocyte, Oxygen, healthy subjects
Brief summary
Under hypoxia or high-altitude hypoxia ,it has been found that 2,3-bisphosphoglycerate(2,3-BPG) in erythrocyte increased and facilitated oxygen release to tissues.Remote Ischemic Conditioning(RIC) can also cause hypoxic conditions in local limbs.Thus,we hypothesize that whether RIC could also increase 2,3-BPG in erythrocyte.
Detailed description
RIC is induced by short-term insulting blood-flow of nonvital distant organs intermittently and has been proved to be effective in ischemic stroke and myocardial infarction(MI).The possible mechanisms of RIC protection is complicated.RIC leads to local ischemia and hypoxia and has been demonstrated to play a role in vital organs through hypoxia inducible factors(HIF) against stroke and MI.Besides HIF, hypoxia or high-altitude hypoxia could also change glycolytic process in erythrocyte through adenosine or sphingosine-1-phosphate(S1P).Accompanying with alternating glucolysis, 2,3-diphosphoglycerate(2,3-BPG) in erythrocyte increases and it also facilitating oxygen release to tissues.Thus,we hypothesize that whether RIC could also increase 2,3-BPG in erythrocyte.There are 8 arms in this trial: All arms are RIC treatment. The level of 2,3-BPG in erythrocyte will be assessed by ELISA before and after the treatment.
Interventions
DEVICEremote ischemic conditioning
RIC is induced by short-term insulting blood-flow of nonvital distant organs intermittently.
Sponsors
Capital Medical University
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
BASIC_SCIENCE
Masking
SINGLE (Investigator)
Eligibility
Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
Yes
Inclusion criteria
1. Age:18-65 years old 2. Healthy adults
Exclusion criteria
1. Individuals with various chronic diseases. 2. Individuals with various acute diseases. 3. Individuals who take any medicines 4. Individuals who have taken health supplements for more than 2 weeks. 5. individuals with BMI\<18.5 or BMI≥24
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Changes of 2,3-BPG levels in erythrocyte | through study completion, an average of 24 hours | Whole blood for testing effect of RIC on 2,3-BPG in Erythrocyte |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Changes of activated partial thromboplastin time(APPT) | through study completion, an average of 24 hours | Whole blood for testing effect of RIC on APPT |
| Changes of activated partial thrombin time(TT) | through study completion, an average of 24 hours | Whole blood for testing effect of RIC on TT |
| Changes of Fibrinogen(FIB) | through study completion, an average of 24 hours | Whole blood for testing effect of RIC on FIB |
| Changes of prothrombin time(PT) | through study completion, an average of 24 hours | Whole blood for testing effect of RIC on PT |
| Changes of hypoxia inducible factor-1(HIF-1) | through study completion, an average of 24 hours | Whole blood for testing effect of RIC on HIF-1 |
| Changes of lower limbs venous blood flow | through study completion, an average of 24 hours | Vascular ultrasound for detecting venous blood flow in lower limbs |
| Changes of D-dimer | through study completion, an average of 24 hours | Whole blood for testing effect of RIC on D-dimer |
Contacts
Primary ContactXunming Ji, MD, PhD
Backup ContactLin Wang
Outcome results
None listed